Last reviewed · How we verify

NCT06001593

Pilot Study of Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation: Double-blind, Randomized, Sham-controlled, Investigator-initiated Trial

Recruiting now Phase 1/Phase 2 Last updated 2 December 2024
What this trial tests

Phase 1/Phase 2 trial testing YPS-201b in Meniere's Disease in 120 participants. Currently enrolling.

Timeline
18 September 2023
Primary endpoint
1 November 2025
31 December 2025

Quick facts

Lead sponsorSeoul National University Hospital
PhasePhase 1/Phase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment120
Start date18 September 2023
Primary completion1 November 2025
Estimated completion31 December 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

Adults 19 to 80, any sex, with Meniere's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This study is a Double-blind, Randomized, Sham-controlled, Investigator-initiated trial. To explore the effectiveness of non-invasive inner ear electrical stimulation of the mastoid behind the ear in controlling auditory symptoms and dizziness in patients with Meniere's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Meniere's Disease

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06001593.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing